This study is currently not recruiting participants.

An Open-label Extension of BPS-314d-MR-PAH-302 in Pulmonary Arterial Hypertension Patients

Investigating the Safety and Tolerability of Long-Term Treatment for Pulmonary Arterial Hypertension (PAH)

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The primary objective of this study is to assess the safety and tolerability of long-term treatment with esuberaprost in patients with PAH.

Detailed description of study

The primary objective of this study is to assess the safety and tolerability of long-term treatment with esuberaprost in patients with PAH.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pulmonary Arterial Hypertension
  • Age: 100 years or below
  • Gender: All

This study investigates the safety and tolerability of a long-term treatment in patients with Pulmonary Arterial Hypertension (PAH). PAH is a condition where the blood pressure in the lungs is higher than normal, which can lead to heart failure if not managed properly.

Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will monitor how participants respond to the treatment over an extended period.

  • Who can participate: Participants aged 18 to 65 years with a confirmed diagnosis of Pulmonary Arterial Hypertension (PAH) are eligible. Key eligibility factors include stable PAH-specific treatment for at least three months and no significant liver or kidney disease.
  • Study details: Participants will be involved in taking either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1807617327

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team